Financial Costs Associated With Monopolies on Biologic Medicines in Australia

Australian Health Review - Australia
doi 10.1071/ah17031
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

CSIRO Publishing

Related search

The Benefits and Costs of Biologic Registers

Nature Clinical Practice Rheumatology
2006English

Consumer Opinions on Adverse Events Associated With Medicines and Vaccines

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2018English

Rational Expectations Equilibrium With Transaction Costs in Financial Markets

Finance Research Letters
Finance
2012English

Leading Financial Literacy in Australia

Applied Finance Letters
2013English

Health Care Costs in Psoriasis Patients Newly Initiated on a Biologic Therapy or Methotrexate

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Psychologic and Biologic Factors Associated With Fatigue in Patients With Persistent Radiculopathy

Pain Management Nursing
Specialized NursingAdvanced
2013English

Impact of Introducing Costs/Qaly Threshold on Access to Oncology Medicines in Slovakia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Access to High Cost Medicines in Australia: Ethical Perspectives

Australia and New Zealand Health Policy
2008English

P032 the Burden Associated With Medicines Reconciliation in Hospitalised Children

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy